Rheumatology

Scleroderma

Questions discussed in this category

When do you consider vascular imaging in patients with Raynaud's and what type of imaging modalities do you utilize?

1 Answer available

Is there a role for cyclophosphamide in refractory digital ischemia in patients with scleroderma?

1 Answer available

How do you utilize methotrexate and/or hydroxychloroquine in the setting of limited scleroderma/CREST?

1 Answer available

What criteria do you use on echocardiogram and PFT to determine who needs further evaluation for CTD-associated pulmonary hypertension?

1 Answer available

Papers discussed in this category

Eur Heart J, 2015 Aug 29

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Eur Respir J, 2019 Jan 24

Diagnosis of pulmonary hypertension.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Case reports in rheumatology, 2017

A Rare Case of Digital Ischemia and Gangrene in ANCA-Associated Vasculitis with Review of the Literature.

Arthritis Rheum,

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

Related Topics in Rheumatology